Methods: In a multicenter randomized placebo-controlled trial, cost-effectiveness was evaluated from a societal perspective. Objective: We aimed to assess cost-effectiveness of small-intestinal release peppermint oil versus placebo in IBS patients. Peppermint oil is a frequently used treatment for IBS, but evidence about cost-effectiveness is lacking. NCT02716285.Ībstract = "Background: Irritable Bowel Syndrome (IBS) is a prevalent, chronic gastrointestinal disorder that imposes a substantial socioeconomic burden. More research and long-term data are necessary to confirm the cost-effectiveness of peppermint oil. The use of peppermint oil, which is a low-cost treatment, can be justified by the modest QALY gains and slightly higher proportion of abdominal pain responders. When using abdominal pain responder as outcome measure for the ICER, peppermint oil has a high probability of being cost-effective. Conclusions: In patients with IBS, small-intestinal release peppermint oil appears to be a cost-effective treatment although there is uncertainty surrounding the ICER. In this case, the acceptability curve showed an 89% probability of being cost-effective. Peppermint oil was also a dominant treatment per additional successfully treated patient according to FDA definitions, that is in 51% of replications. The net-benefit acceptability curve showed that peppermint oil has a 56% probability of being cost-effective at a conservative willingness-to-pay threshold of €10.000/QALY. Peppermint oil was also more effective but at higher cost in 31% of replications. Peppermint oil was a dominant treatment compared to placebo in 46% of bootstrap replications. Results: The analysis comprised 126 patients (N = 64 placebo, N = 62 small-intestinal release peppermint oil). Cost-utility and uncertainty were estimated using non-parametric bootstrapping. The incremental cost-effectiveness ratios (ICERs) were expressed as (1) incremental costs per Quality Adjusted Life Years (QALY), and (2) incremental costs per successfully treated patient, that is per abdominal pain responder (according to FDA definitions), both after an eight-week treatment period with placebo versus peppermint oil. For additional information visit Linking to and Using Content from MedlinePlus.Background: Irritable Bowel Syndrome (IBS) is a prevalent, chronic gastrointestinal disorder that imposes a substantial socioeconomic burden. Any duplication or distribution of the information contained herein is strictly prohibited without authorization. Links to other sites are provided for information only - they do not constitute endorsements of those other sites. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. This site complies with the HONcode standard for trustworthy health information: verify here. Learn more about A.D.A.M.'s editorial policy editorial process and privacy policy. is among the first to achieve this important distinction for online health information and services. follows rigorous standards of quality and accountability. is accredited by URAC, for Health Content Provider (URAC's accreditation program is an independent audit to verify that A.D.A.M.
0 Comments
Leave a Reply. |